Which has stronger valuation & earnings, KLRA or ANL?

Adlai Nortye has higher revenue and earnings than Kailera Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kailera Therapeutics N/A N/A -$148.96M -$3.65 thousand N/A Adlai Nortye $5M 178.39 -$35.53M N/A N/A

Is KLRA or ANL more profitable?

Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Adlai Nortye N/A N/A N/A

Does the media refer more to KLRA or ANL?

In the previous week, Kailera Therapeutics and Kailera Therapeutics both had 4 articles in the media. Adlai Nortye's average media sentiment score of 0.40 beat Kailera Therapeutics' score of -0.09 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Adlai Nortye 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, ANL or COAG?

Hemab Therapeutics has lower revenue, but higher earnings than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 178.39 -$35.53M N/A N/A Hemab Therapeutics N/A N/A N/A -$24.78 N/A

Is ANL or COAG more profitable?

Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Hemab Therapeutics N/A N/A N/A

Does the media prefer ANL or COAG?

In the previous week, Adlai Nortye had 3 more articles in the media than Hemab Therapeutics. MarketBeat recorded 4 mentions for Adlai Nortye and 1 mentions for Hemab Therapeutics. Adlai Nortye's average media sentiment score of 0.40 beat Hemab Therapeutics' score of 0.00 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hemab Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, ANL or NBTX?

Nanobiotix has higher revenue and earnings than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 178.39 -$35.53M N/A N/A Nanobiotix $36.87M 57.21 -$27.11M N/A N/A

Is ANL or NBTX more profitable?

Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Nanobiotix N/A N/A N/A

Does the media favor ANL or NBTX?

In the previous week, Adlai Nortye had 1 more articles in the media than Nanobiotix. MarketBeat recorded 4 mentions for Adlai Nortye and 3 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.63 beat Adlai Nortye's score of 0.40 indicating that Nanobiotix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nanobiotix 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, ANL or PVLA?

Adlai Nortye has higher revenue and earnings than Palvella Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 178.39 -$35.53M N/A N/A Palvella Therapeutics N/A N/A -$41.72M -$4.83 N/A

Is ANL or PVLA more profitable?

Adlai Nortye's return on equity of 0.00% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Palvella Therapeutics N/A -47.84% -38.33%

Does the media favor ANL or PVLA?

In the previous week, Palvella Therapeutics had 9 more articles in the media than Adlai Nortye. MarketBeat recorded 13 mentions for Palvella Therapeutics and 4 mentions for Adlai Nortye. Palvella Therapeutics' average media sentiment score of 1.10 beat Adlai Nortye's score of 0.40 indicating that Palvella Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palvella Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ANL or AUPH?

Aurinia Pharmaceuticals has higher revenue and earnings than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 178.39 -$35.53M N/A N/A Aurinia Pharmaceuticals $283.05M 7.66 $287.20M $2.29 7.11

Does the media favor ANL or AUPH?

In the previous week, Aurinia Pharmaceuticals had 4 more articles in the media than Adlai Nortye. MarketBeat recorded 8 mentions for Aurinia Pharmaceuticals and 4 mentions for Adlai Nortye. Aurinia Pharmaceuticals' average media sentiment score of 1.60 beat Adlai Nortye's score of 0.40 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aurinia Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Adlai Nortye (ANL) Competitors

$13.85 +0.22 (+1.61%)

Closing price 09/2/2026 04:00 PM Eastern

Extended Trading

$14.16 +0.32 (+2.27%)

As of 09/2/2026 07:30 PM Eastern

Compare

ANL vs. KLRA, COAG, NBTX, PVLA, and AUPH

Should you buy Adlai Nortye stock or one of its competitors? Adlai Nortye's main competitors and comparable companies include Kailera Therapeutics (KLRA), Hemab Therapeutics (COAG), Nanobiotix (NBTX), Palvella Therapeutics (PVLA), and Aurinia Pharmaceuticals (AUPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Adlai Nortye compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Adlai Nortye (NASDAQ:ANL) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Adlai Nortye	N/A	N/A	N/A

Adlai Nortye has higher revenue and earnings than Kailera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A
Adlai Nortye	$5M	178.39	-$35.53M	N/A	N/A

35.2% of Adlai Nortye shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kailera Therapeutics presently has a consensus target price of $42.75, indicating a potential upside of 169.72%. Adlai Nortye has a consensus target price of $24.25, indicating a potential upside of 75.09%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Kailera Therapeutics is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Kailera Therapeutics and Kailera Therapeutics both had 4 articles in the media. Adlai Nortye's average media sentiment score of 0.40 beat Kailera Therapeutics' score of -0.09 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Adlai Nortye	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Adlai Nortye beats Kailera Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Adlai Nortye compare to Hemab Therapeutics?

Adlai Nortye (NASDAQ:ANL) and Hemab Therapeutics (NASDAQ:COAG) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

In the previous week, Adlai Nortye had 3 more articles in the media than Hemab Therapeutics. MarketBeat recorded 4 mentions for Adlai Nortye and 1 mentions for Hemab Therapeutics. Adlai Nortye's average media sentiment score of 0.40 beat Hemab Therapeutics' score of 0.00 indicating that Adlai Nortye is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hemab Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Hemab Therapeutics	N/A	N/A	N/A

35.2% of Adlai Nortye shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Adlai Nortye presently has a consensus target price of $24.25, suggesting a potential upside of 75.09%. Hemab Therapeutics has a consensus target price of $51.40, suggesting a potential upside of 14.99%. Given Adlai Nortye's stronger consensus rating and higher possible upside, analysts clearly believe Adlai Nortye is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Hemab Therapeutics has lower revenue, but higher earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	178.39	-$35.53M	N/A	N/A
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A

Summary

Adlai Nortye beats Hemab Therapeutics on 6 of the 6 factors compared between the two stocks.

How does Adlai Nortye compare to Nanobiotix?

Adlai Nortye (NASDAQ:ANL) and Nanobiotix (NASDAQ:NBTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Nanobiotix has higher revenue and earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	178.39	-$35.53M	N/A	N/A
Nanobiotix	$36.87M	57.21	-$27.11M	N/A	N/A

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Nanobiotix	N/A	N/A	N/A

Adlai Nortye has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Adlai Nortye presently has a consensus target price of $24.25, indicating a potential upside of 75.09%. Nanobiotix has a consensus target price of $37.33, indicating a potential downside of 10.41%. Given Adlai Nortye's stronger consensus rating and higher probable upside, research analysts plainly believe Adlai Nortye is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Adlai Nortye had 1 more articles in the media than Nanobiotix. MarketBeat recorded 4 mentions for Adlai Nortye and 3 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.63 beat Adlai Nortye's score of 0.40 indicating that Nanobiotix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanobiotix	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Adlai Nortye beats Nanobiotix on 6 of the 11 factors compared between the two stocks.

How does Adlai Nortye compare to Palvella Therapeutics?

Adlai Nortye (NASDAQ:ANL) and Palvella Therapeutics (NASDAQ:PVLA) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 17.2% of Palvella Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Adlai Nortye has higher revenue and earnings than Palvella Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	178.39	-$35.53M	N/A	N/A
Palvella Therapeutics	N/A	N/A	-$41.72M	-$4.83	N/A

In the previous week, Palvella Therapeutics had 9 more articles in the media than Adlai Nortye. MarketBeat recorded 13 mentions for Palvella Therapeutics and 4 mentions for Adlai Nortye. Palvella Therapeutics' average media sentiment score of 1.10 beat Adlai Nortye's score of 0.40 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palvella Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adlai Nortye has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market.

Adlai Nortye's return on equity of 0.00% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Palvella Therapeutics	N/A	-47.84%	-38.33%

Adlai Nortye currently has a consensus target price of $24.25, suggesting a potential upside of 75.09%. Palvella Therapeutics has a consensus target price of $209.14, suggesting a potential upside of 36.74%. Given Adlai Nortye's higher probable upside, equities research analysts plainly believe Adlai Nortye is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Palvella Therapeutics beats Adlai Nortye on 7 of the 13 factors compared between the two stocks.

How does Adlai Nortye compare to Aurinia Pharmaceuticals?

Adlai Nortye (NASDAQ:ANL) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Adlai Nortye presently has a consensus target price of $24.25, indicating a potential upside of 75.09%. Aurinia Pharmaceuticals has a consensus target price of $17.67, indicating a potential upside of 8.45%. Given Adlai Nortye's higher possible upside, analysts clearly believe Adlai Nortye is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

Adlai Nortye has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Adlai Nortye's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Adlai Nortye's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%

Aurinia Pharmaceuticals has higher revenue and earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	178.39	-$35.53M	N/A	N/A
Aurinia Pharmaceuticals	$283.05M	7.66	$287.20M	$2.29	7.11

In the previous week, Aurinia Pharmaceuticals had 4 more articles in the media than Adlai Nortye. MarketBeat recorded 8 mentions for Aurinia Pharmaceuticals and 4 mentions for Adlai Nortye. Aurinia Pharmaceuticals' average media sentiment score of 1.60 beat Adlai Nortye's score of 0.40 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurinia Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Aurinia Pharmaceuticals beats Adlai Nortye on 11 of the 14 factors compared between the two stocks.

Get Adlai Nortye News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANL vs. The Competition

Export

Metric	Adlai Nortye	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$877.74M	$3.99B	$7.20B	$12.67B
Dividend Yield	N/A	3.61%	2.53%	8.56%
P/E Ratio	N/A	12.25	272.66	25.23
Price / Sales	178.39	1,404.66	634.53	104.56
Price / Cash	N/A	105.29	76.98	52.08
Price / Book	4.15	16.51	12.97	6.10
Net Income	-$35.53M	-$22.72M	$3.47B	$348.86M
7 Day Performance	-3.28%	-1.22%	-0.11%	-1.90%
1 Month Performance	6.62%	11.26%	6.75%	1.96%
1 Year Performance	678.09%	53.07%	25.08%	15.30%

Adlai Nortye Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANL Adlai Nortye	1.7385 of 5 stars	$13.85 +1.6%	$24.25 +75.1%	+673.7%	$877.74M	$5M	N/A	127
KLRA Kailera Therapeutics	2.2643 of 5 stars	$18.44 +3.9%	$42.75 +131.8%	N/A	$2.39B	N/A	N/A	145
COAG Hemab Therapeutics	2.3774 of 5 stars	$49.19 -0.9%	$51.40 +4.5%	N/A	$2.30B	N/A	N/A	72
NBTX Nanobiotix	1.0817 of 5 stars	$44.50 +7.2%	$37.33 -16.1%	+392.8%	$2.25B	$36.87M	N/A	100	Gap Up High Trading Volume
PVLA Palvella Therapeutics	2.6494 of 5 stars	$154.33 +4.1%	$209.14 +35.5%	+190.2%	$2.22B	$42.81M	N/A	N/A	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANL) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adlai Nortye (ANL) Competitors

ANL vs. KLRA, COAG, NBTX, PVLA, and AUPH

How does Adlai Nortye compare to Kailera Therapeutics?

Summary

How does Adlai Nortye compare to Hemab Therapeutics?

Summary

How does Adlai Nortye compare to Nanobiotix?

Summary

How does Adlai Nortye compare to Palvella Therapeutics?

Summary

How does Adlai Nortye compare to Aurinia Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANL vs. The Competition

Adlai Nortye Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adlai Nortye (ANL) Competitors

ANL vs. KLRA, COAG, NBTX, PVLA, and AUPH

How does Adlai Nortye compare to Kailera Therapeutics?

Is KLRA or ANL more profitable?

Which has stronger valuation & earnings, KLRA or ANL?

Do institutionals and insiders have more ownership in KLRA or ANL?

Do analysts prefer KLRA or ANL?

Does the media refer more to KLRA or ANL?

Summary

How does Adlai Nortye compare to Hemab Therapeutics?

Does the media prefer ANL or COAG?

Is ANL or COAG more profitable?

Do institutionals and insiders believe in ANL or COAG?

Do analysts prefer ANL or COAG?

Which has preferable valuation & earnings, ANL or COAG?

Summary

How does Adlai Nortye compare to Nanobiotix?

Which has better earnings & valuation, ANL or NBTX?

Do institutionals & insiders believe in ANL or NBTX?

Is ANL or NBTX more profitable?

Which has more risk and volatility, ANL or NBTX?

Do analysts recommend ANL or NBTX?

Does the media favor ANL or NBTX?

Summary

How does Adlai Nortye compare to Palvella Therapeutics?

Do institutionals and insiders believe in ANL or PVLA?

Which has higher earnings and valuation, ANL or PVLA?

Does the media favor ANL or PVLA?

Which has more risk and volatility, ANL or PVLA?

Is ANL or PVLA more profitable?

Do analysts prefer ANL or PVLA?

Summary

How does Adlai Nortye compare to Aurinia Pharmaceuticals?

Do analysts recommend ANL or AUPH?

Which has more volatility & risk, ANL or AUPH?

Do insiders and institutionals have more ownership in ANL or AUPH?

Is ANL or AUPH more profitable?

Which has better earnings and valuation, ANL or AUPH?

Does the media favor ANL or AUPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANL vs. The Competition

Adlai Nortye Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools